These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1175123)

  • 21. Tumor growth patterns in multiple myeloma.
    Hokanson JA; Brown BW; Thompson JR; Drewinko B; Alexanian R
    Cancer; 1977 Mar; 39(3):1077-84. PubMed ID: 912647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential therapy compared with combination therapy in multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):163-71. PubMed ID: 1111465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple myeloma without detectable Ig synthesis.
    Ferraris AM; Haupt E; Ratti M
    Acta Haematol; 1979; 62(5-6):257-61. PubMed ID: 121666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple myeloma. II. The value of melphalan.
    Bernard DB; Lynch SR; Bothwell TH; Bezwoda WR; Stevens K; Shulman G
    S Afr Med J; 1974 May; 48(24):1026-8. PubMed ID: 4835772
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
    Case DC; Sonneborn HL; Paul SD; Hayes DM; Dorsk BM; Carroll RJ; Bove L
    Oncology; 1985; 42(3):137-40. PubMed ID: 3858763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE; Pruzanski W
    Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vindesine therapy in melphalan-resistant multiple myeloma.
    Houwen B; Ockhuizen T; Marrink J; Nieweg HO
    Eur J Cancer (1965); 1981 Feb; 17(2):227-32. PubMed ID: 7262159
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine.
    Arch Intern Med; 1975 Jan; 135(1):157-62. PubMed ID: 1111464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term survival of a patient with multiple myeloma--a cure? A case report.
    Dutcher JP; Wiernik PH
    Cancer; 1984 May; 53(10):2069-72. PubMed ID: 6704893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
    Shimizu K; Kamiya O; Hirabayashi N; Ichikawa A; Kawashima K; Kobayashi M; Mizuno H; Nagura E; Nitta M; Saito H; Sao H; Shibata T; Takeyama H
    Jpn J Cancer Res; 1999 Mar; 90(3):355-60. PubMed ID: 10359052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Results of the treatment of myeloma with a vincristine-melphalan combination].
    Roux H; d'Omezon Y; Gaborit P; Eisinger F; Serratrice G
    Rev Rhum Mal Osteoartic; 1979; 46(7-9):443-8. PubMed ID: 315613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
    Presant CA; Klahr C
    Cancer; 1978 Sep; 42(3):1222-7. PubMed ID: 698913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cytomorphological, immunochemical and therapeutic aspects of multiple myeloma].
    Maroncelli P; Casalino C
    Minerva Med; 1973 Feb; 64(8):337-57. PubMed ID: 4120544
    [No Abstract]   [Full Text] [Related]  

  • 36. Prognostic factors for multiple myeloma in the dog.
    Matus RE; Leifer CE; MacEwen EG; Hurvitz AI
    J Am Vet Med Assoc; 1986 Jun; 188(11):1288-92. PubMed ID: 3721983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
    Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
    Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy.
    Alexanian R; Migliore PJ
    J Lab Clin Med; 1970 Feb; 75(2):225-33. PubMed ID: 5414404
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
    Bergsagel DE; Cowan DH; Hasselback R
    Can Med Assoc J; 1972 Nov; 107(9):851-5. PubMed ID: 4653931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
    Baldini L; Radaelli F; Chiorboli O; Fumagalli S; Cro L; Segala M; Cesana BM; Polli EE; Maiolo AT
    Cancer; 1991 Jul; 68(1):62-7. PubMed ID: 2049754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.